{
    "document_name": "benh-rubella.json",
    "document_name_accent": "benh rubella.json",
    "document_title": "Rubella (German measles): Causes, symptoms, diagnosis and treatment",
    "document_category": "Infectious",
    "subsection_name": "benh-rubella.json_9_Rubella prevention",
    "subsection_content": "Vaccination\nRubella vaccine is a live attenuated strain and a single dose provides more than 95% long-term immunity, similar to that caused by natural infection.\nRubella vaccination is an effective and long-lasting way to prevent the disease\nRubella vaccine is available as a monovalent (a vaccine that targets only one pathogen) or more commonly in combination with other vaccines such as childhood measles (MR), measles and mumps (MR) vaccines. MMR), or measles, mumps and varicella (MMRV).\nSide effects after vaccination are usually mild. They may include pain and redness at the injection site, mild fever, rash, and muscle pain.\nWHO recommends that all countries that have not yet introduced Rubella vaccination should consider using existing, well-established measles vaccination programmes. To date, four WHO regions have set targets to eliminate preventable causes of birth defects. In 2015, WHO's Americas became the first region in the world to be declared free of endemic Rubella transmission.\nThe number of countries using Rubella vaccine in their national programs continues to increase steadily. As of December 2018, 168 out of 194 countries used Rubella vaccine and global coverage was estimated at 69%. Reported cases of Rubella have decreased by 97%, from 670 894 cases in 102 countries in 2000 to 14 621 cases in 151 countries in 2018. CRS rates are highest in African regions and WHO Southeast Asia where vaccination rates are lowest.\nBased on the 2018 Global Vaccine Action Plan (GVAP) Assessment Report of the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, Rubella control is lagging behind, with 26 countries still introduce the vaccine, while two regions (Africa and the Eastern Mediterranean) have not yet set goals for eliminating or controlling Rubella.\nSAGE recommends that Rubella vaccination should be introduced into vaccination programs as quickly as possible, to ensure that further benefits in Rubella control can be achieved. As one of the founding members of the Measles & Rubella Initiative, WHO provides technical support to governments and communities to improve routine immunization programs.\nRubella IgG antibody test\nIf you want to know whether your body has immunity to protect against Rubella, you should go to the doctor to be tested for Rubella IgG antibodies. This is a natural protective immunity produced when the body has been infected and recovered from the disease. If the Rubella IgG result is > 10 IU/L, the body has protective immunity. In case the result is ≤ 10 IU/L, you should get vaccinated to prevent disease.\nThe Testing Center, Tam Anh General Hospital is invested in spacious construction, arranged with a modern and synchronous equipment system, meeting Biosafety level 2 standards. At the same time, testing services are performed. with a system of modern equipment and machinery. Quantitative IgM antibody test; IgG Rubella is performed on the automatic Cobas 6000 and Cobas Pro systems of Roche.\nTo schedule an appointment at TAM ANH General Hospital, customers can fill out information here, or contact via:\nThrough the article, people also understand more about Rubella disease or more precisely, Rubella virus. With the signs and symptoms described above, those who show symptoms of the disease should calmly find out the cause and consult a doctor to be able to prevent and treat German measles conveniently and quickly. quickly",
    "subsection_title": "benh rubella.json. Rubella prevention",
    "subsection_data": "benh rubella.json. Rubella prevention\nVaccination\nRubella vaccine is a live attenuated strain and a single dose provides more than 95% long-term immunity, similar to that caused by natural infection.\nRubella vaccination is an effective and long-lasting way to prevent the disease\nRubella vaccine is available as a monovalent (a vaccine that targets only one pathogen) or more commonly in combination with other vaccines such as childhood measles (MR), measles and mumps (MR) vaccines. MMR), or measles, mumps and varicella (MMRV).\nSide effects after vaccination are usually mild. They may include pain and redness at the injection site, mild fever, rash, and muscle pain.\nWHO recommends that all countries that have not yet introduced Rubella vaccination should consider using existing, well-established measles vaccination programmes. To date, four WHO regions have set targets to eliminate preventable causes of birth defects. In 2015, WHO's Americas became the first region in the world to be declared free of endemic Rubella transmission.\nThe number of countries using Rubella vaccine in their national programs continues to increase steadily. As of December 2018, 168 out of 194 countries used Rubella vaccine and global coverage was estimated at 69%. Reported cases of Rubella have decreased by 97%, from 670 894 cases in 102 countries in 2000 to 14 621 cases in 151 countries in 2018. CRS rates are highest in African regions and WHO Southeast Asia where vaccination rates are lowest.\nBased on the 2018 Global Vaccine Action Plan (GVAP) Assessment Report of the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, Rubella control is lagging behind, with 26 countries still introduce the vaccine, while two regions (Africa and the Eastern Mediterranean) have not yet set goals for eliminating or controlling Rubella.\nSAGE recommends that Rubella vaccination should be introduced into vaccination programs as quickly as possible, to ensure that further benefits in Rubella control can be achieved. As one of the founding members of the Measles & Rubella Initiative, WHO provides technical support to governments and communities to improve routine immunization programs.\nRubella IgG antibody test\nIf you want to know whether your body has immunity to protect against Rubella, you should go to the doctor to be tested for Rubella IgG antibodies. This is a natural protective immunity produced when the body has been infected and recovered from the disease. If the Rubella IgG result is > 10 IU/L, the body has protective immunity. In case the result is ≤ 10 IU/L, you should get vaccinated to prevent disease.\nThe Testing Center, Tam Anh General Hospital is invested in spacious construction, arranged with a modern and synchronous equipment system, meeting Biosafety level 2 standards. At the same time, testing services are performed. with a system of modern equipment and machinery. Quantitative IgM antibody test; IgG Rubella is performed on the automatic Cobas 6000 and Cobas Pro systems of Roche.\nTo schedule an appointment at TAM ANH General Hospital, customers can fill out information here, or contact via:\nThrough the article, people also understand more about Rubella disease or more precisely, Rubella virus. With the signs and symptoms described above, those who show symptoms of the disease should calmly find out the cause and consult a doctor to be able to prevent and treat German measles conveniently and quickly. quickly"
}